Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2000

View Archived Issues

BioQuest and Biovector Therapeutics to collaborate on HIV vaccine

Dura expands inhaler technology platform

Pharmacia to use Biacore's lead selection technology

Lundbeck and M&E Biotech to cooperate on neurodegenerative disease research

Humalog now available in Europe to treat children with diabetes

Idec enters two agreements for prostate cancer immunotherapy

Corixa receives milestone from Organon for RA collaboration

Raloxifene shows good uterine safety profile

Lilly and Arena to develop GPCRs as screening targets

Coley initiates phase I/II trials of CpG-7909 for cancer

Company Profile: Renovo

Apoptosis-initiating gene acquired by Idun

NIH research sheds light on chronic hepatitis C

CV Therapeutics develops sustained-release formulations of ranolazine

ATP-sensitive K+ channel blockers reportedly useful for vagal nervous system dysfunction

Novel compounds that inhibit hematopoietic cell activation in development at AstraZeneca

Immunomodulators from Gruenenthal affect IL-10 and IL-12 production

Aventis prepares new selective factor VIIa inhibitors

Preparation, activity and use of inhibitors of Th2-type cytokine production described by Sumitomo

Teveten now available in the U.K. for the treatment of hypertension

Anti-HIV activity demonstrated for natural product used in Japan for hepatitis

New controlled-release, microencapsulated HBV vaccine prepared in China

DepoMed reports phase I results for Metformin GR

Biovector Therapeutics initiates phase II trial of melanoma vaccine

Inhalable MS drug enters phase I trials

BMS temporarily withdraws Vanlev NDA

Artemis and Max Planck begin international genetic screening project with zebrafish

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...